Effects of the long acting β agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids

Thorax

Volumn 52, Issue 6, 1997, Pages 535-539

  Van Der Molen, T ^b   Postma, D S ^a   Turner, M O ^b   Meyboom de Jong, B ^b   Malo, J L ^b   Chapman, K ^b   Grossman, R ^b   De Graaff, C S ^b   Riemersma, R A ^b   Sears, M R ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

Asthma; Formoterol; Inhaled corticosteroids; Long acting agonists

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 8544242685     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.6.535     Document Type: Article

References (18)

1. Barnes PJ. A new approach to the treatment of asthma. N Engl J Med 1989;321:1517-27.
2. van Schayck CP, Dompeling E, van Herwaarden CLA, Folgering H, Verbeek ALM, van der Hoogen HJM, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991;303:1426-31.
3. 2-agonist treatment. Am Rev Respir Dis 1993;148:707-12.
4. 2-agonist controversy. Observations, explanations,and relationship to asthma epidemiology. Drug Safety 1994;2:259-83.
5. 2-agonists in asthma. N Engl J Med 1992;327:1204-8.
6. Dompeling E, van Schayck CP, van Grunsven PM, van Herwaarden CLA, Akkermans R, Molema J, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4 year prospective study. Ann Intern Med 1993;118:770-8.
7. Sears MR, Taylor DR, Print CG, Lake DC, Li Q, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
8. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
9. Quanjer PH. Standardized lung function testing. Bull Eur Physiopathol Respir 1983;19(Suppl 5):1-95.
10. Greening AP, Ind PW, Northfield M, Shaw G, Allen & Hanburys Limited UK Study Group. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-24.
11. Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, Knight A, et al. Sustained improvement in asthma with long term use of formoterol fumarate. Ann Allergy 1992; 69:415-20.
12. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7.
13. Hekking PR, Maesen F, Greefhorst A, Prins J, Tan I, Zweers P. Long-term efficacy of formoterol compared to salbutamol. Lung 1990;Suppl:76-82.
14. Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, Knight A, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991;144:622-5.
15. Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. Am Rev Respir Dis 1990; 142:571-5.
16. 2-receptor in asthmatic patients. Allergy 1992;47:477-83.
17. Britton MG, Earnshaw JS, Palmer JB. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992;5:1062-7.
18. Kraan J, Koëter GH, van der Mark ThW, Sluiter HJ, de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985;76:628-36.